TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05584696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green light exposure
Description: The experimental group wears green color glasses ten minutes before surgery until it ends.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal light exposure
Description: The control group wears green color glasses ten minutes before surgery until it ends.
Study: NCT05705284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary medication review
Description: Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
Study: NCT05219747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mucoadhesive film containing Acmella oleracea extract
Description: Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mucoadhesive film without Acmella oleracea extract
Description: Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
Study: NCT06580990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: specific neck exercises with the Spinetrack
Description: This group will receive an telerehabilitation exercise programme for the deep neck musculature using the spinetrack

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: specific neck exercises
Description: This group will receive a telerehabilitation programme with exercise for the deep neck musculature
Study: NCT05095077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 MG
Description: Single dose on study day 1/2
Study: NCT05093660

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood specimen collection
Description: Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood specimen collection
Description: Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva specimen collection
Description: Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva specimen collection
Description: Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
Study: NCT05471089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Applied to both arms/groups
Study: NCT06016868

Intervention type: PROCEDURE
Intervention: Tumor tissue
Description: Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
Study: NCT05168020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Behavior Fading for Social Anxiety
Description: Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unhealthy Behavior Fading
Description: Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
Study: NCT05431504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib in combination with endocrine therapy by Physicians choice
Description: Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses
Study: NCT06584266

Intervention type: DIAGNOSTIC_TEST
Intervention: Transoesophageal echocardiography
Description: Imaging data obtained with transoesophageals echocardiography will be retained as well as data from transthoracic echocardiography and from other imaging modalities, if available
Study: NCT05095077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to active IMP
Study: NCT06584266

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Cathether ablation of atrial fibrillation substrate using one of available methods.
Study: NCT05974267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 60 mg
Description: Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine
Description: Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine
Description: Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
Study: NCT06584058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP737
Description: \[14C\]HPP737 oral preparation, 20mg（150μCi）, once
Study: NCT06583278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study: NCT06584461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (drug)
Description: IV lidocaine, administered once during the induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: IV placebo (normal saline), administered once during the induction of anesthesia.
Study: NCT06583889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or urokinase within the thrombosed sinuses.
Study: NCT04430933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
Study: NCT06093451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Moderate agitation: 120 mcg Severe agitation: 180 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam 2 MG/ML
Description: 2 mg
Study: NCT05974267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine
Description: Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-Proguanil
Description: Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 200 mg
Description: Participants will receive single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 660mg
Description: Participants will receive single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
Study: NCT05818475

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR PCI indication and planning
Description: Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
Study: NCT06096766

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
Study: NCT04731233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factor (PRGF) Supplementation
Description: After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
Study: NCT06482957

Intervention type: OTHER
Intervention: Surveys
Description: Complete surveys

Intervention type: OTHER
Intervention: Blood Collection
Description: Undergo blood collection

Intervention type: OTHER
Intervention: Saliva Collection
Description: Undergo salvia collection

Intervention type: OTHER
Intervention: Urine Collection
Description: Undergo urine collection

Intervention type: OTHER
Intervention: Stool Collection
Description: Undergo stool collection

Intervention type: OTHER
Intervention: Tissue collection
Description: Undergo tissue collection

Intervention type: OTHER
Intervention: Physical Activity Monitoring
Description: FitBit will be worn to track physical activity
Study: NCT04854122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise intervention
Description: The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care / Sham intervention
Description: The control condition consists of usual activities.
Study: NCT05342727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
Study: NCT05879016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Correction Technique
Description: A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascia Correction Technique
Description: Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Star Taping Technique
Description: 4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: I shape tape will be adhered for sham purpose without applying any tension.
Study: NCT04879576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
Study: NCT05413655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX039
Description: The dosage form of EX039 is the capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX039
Description: The dosage form of EX039 is the capsule for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dosage form of Placebo is the capsule for oral use
Study: NCT05870358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 MG
Description: In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
Study: NCT06452680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preserving IPL during surgery
Description: IPL was preserved during surgery
Study: NCT05249504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIVIFRAIL
Description: VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychology
Description: Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal autonomy
Description: Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community resources
Description: Learn about community resources

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard recommendations
Description: Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
Study: NCT06115590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Nutritional intervention hypothesized to have an acute anxiolytic effect
Study: NCT05573126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0062
Description: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
Study: NCT04430933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Study: NCT05573126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0062
Description: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0062
Description: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
Study: NCT06245668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SaCoVLM™ video laryngeal mask
Description: The SaCoVLM™ video laryngeal mask will be placed directly into the hypopharyngeal space until resistance is felt, following the recommended instructions for use.
Study: NCT05891496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semagllutide will be administered once weekly subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: Semagllutide will be administered once weekly subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to semaglutide will be administered once weekly subcutaneously.
Study: NCT05660408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA LP (DP1)
Description: This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA LP (DP1)
Description: This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)
Study: NCT04430933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel/Carboplatin
Description: Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Study: NCT05660408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA LP (DP1)
Description: This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA LP (DP1)
Description: This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65 RNA LP (DP1)
Description: This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)
Study: NCT06245668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Description: The LMA Supreme will be inserted directly by hand and placed into the hypopharyngeal space until resistance is felt, as per the recommended instructions for use.
Study: NCT04430933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
Study: NCT03967834

Intervention type: OTHER
Group type: OTHER
Intervention: Patient with Soft Tissue Sarcoma
Description: * Tumor specimens will be collected for the study at diagnosis.~* A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~* Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years.
Study: NCT06211998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2